🟢 Moderna is trading 5% up in pre-market with no clear company-specific catalyst

Moderna is trading 5.15% up now at $140.19 after a sharp prior-session pullback, with no clear fresh company-specific catalyst for the rebound.

• The Phase 3 INTerpath-001 trial met its recurrence-free and distant-metastasis-free survival endpoints, supporting renewed investor interest in Moderna’s oncology pipeline.
• Available coverage attributes the August 20 decline to profit-taking and valuation concerns, not a new August 21 announcement.
• The broader market is modestly higher pre-market; confidence in the rebound’s cause is low.